Shares of Vincerx Pharma, Inc. (VINC) are down over 29% in premarket trading Monday, on news of the company terminating its previously signed binding Term Sheet for a reverse merger with Oqory Inc. and Vivasor Inc.
As a result of this termination, Vincerx's board of directors will reassess its strategic alternatives, including options such as out-licensing, mergers and acquisitions (including reverse mergers), asset and technology sales, or even winding down operations.
As of February 26, 2025, Vincerx reported having approximately $3.9 million in cash, which is expected to fund the company's operations through the late second quarter 2025. VINC closed Friday's (Feb.28 2025) trading at $1.09 down by 13.49 percent. In premarket trading Monday the stock is down by 29.36 percent at $0.82 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.